We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Simulations Plus Inc | NASDAQ:SLP | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 48.21 | 46.90 | 50.00 | 0 | 12:00:13 |
Conference Call to be on Monday, April 9, 2018, at 4:15 PM ET
Simulations Plus, Inc. (Nasdaq: SLP) announced today that it expects to file its quarterly report on Form 10-Q for the second quarter of its 2018 fiscal year, the period ended February 28, 2018, on Monday, April 9, 2018.
The Company will host a conference call on April 9, 2018, at 4:15 p.m. Eastern Time. All interested parties are invited to join the call by registering here. On registering, you will receive a confirmation e-mail with instructions for joining the call. Please dial in five to ten minutes prior to the scheduled start time. For listen-only mode, you may dial (562) 247-8422, and enter access code 553-540-204. A replay will be available on the Simulations Plus website following the call.
About Simulations Plus, Inc.
Simulations Plus, Inc. is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical and biotechnology agents. Our software is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies and regulatory agencies worldwide. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading software provider for physiologically based pharmacokinetic modeling and simulation. For more information, visit our website at www.simulations-plus.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180404005474/en/
Simulations Plus Investor RelationsMs. Renee Bouche, 661-723-7723renee@simulations-plus.comorHayden IRMr. Cameron Donahue, 651-653-1854cameron@haydenir.com
1 Year Simulations Plus Chart |
1 Month Simulations Plus Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions